Genomic Variant Interpretation for Drug Target Discovery
Analyze genomic variants to identify drug targets with regulatory-ready assessments
What You Can Do
You can translate raw variant catalogs and NGS data into actionable target hypotheses by synthesizing variant effect predictions, population frequency metrics, disease association evidence, and protein interaction networks. This skill automates the connection between molecular findings and clinical relevance, producing comprehensive variant assessments that justify target selection across pharmaceutical development stages and support regulatory submissions.
Features
Evaluates missense, loss-of-function, and regulatory impact consequences using computational annotations
Analyzes gnomAD frequencies, internal cohort data, and allele balance to establish variant significance
Integrates GWAS catalog evidence and literature context to link variants to therapeutic indications
Maps variants to protein interactions and biological pathways relevant to drug mechanism
Scores target tractability including existing inhibitors, biomarker potential, and therapeutic feasibility
Generates 21 CFR Part 11-compliant reports with full data traceability for IND submissions
Creates variant assessment summaries tailored for medicinal chemistry, clinical ops, and leadership stakeholders
Example Output
Example 1: GWAS Variant Prioritization Report
Variant: rs12345678 (BRCA1 p.Arg1699Gln)
- Effect Prediction: Missense variant; in silico tools predict deleterious impact (SIFT score 0.02, PolyPhen-2 probably damaging)
- Population Data: Frequency 0.0012 in gnomAD; enriched 3.2-fold in breast cancer cohort (p=1.2e-8)
- Disease Association: 47 literature citations linking BRCA1 loss-of-function to HER2+ breast cancer; 15 active clinical trials targeting BRCA1 pathway
- Druggability Score: 8.2/10 (high target tractability); 12 existing PARP inhibitors; potential companion diagnostic biomarker
- Regulatory Ready: ✓ Validated assay; ✓ Literature evidence; ✓ Mechanism rationale
Example 2: RNA-seq Rare Variant Assessment
Variant: Novel insertion NM_001234.5 c.2456_2457insAGA (EGFR exon 19)
- Functional Impact: Frameshift leading to premature stop codon (p.Ala819fs)
- Expression Context: Detected in 18/200 patient samples with lung adenocarcinoma; absent in 1000 controls
- Pathway Relevance: Complete loss of kinase domain; predicted non-functional EGFR
- Clinical Translation: Matches erlotinib-resistant phenotype; candidate for next-gen TKI screening
- Regulatory Flag: De novo variant; requires independent validation and functional confirmation for IND roadmap
What's Included
- SKILL.md: Complete variant interpretation workflow with standard operating procedures
- Variant Assessment Template: Structured report framework for documenting variant classification, evidence synthesis, and regulatory justification
- Functional Annotation Checklist: Step-by-step guide for evaluating effect predictions, population metrics, and disease associations
- Druggability Scoring Framework: Quantitative assessment criteria and weighting for target tractability evaluation
- Regulatory Compliance Worksheet: 21 CFR Part 11 requirements checklist and data traceability documentation table
Who It's For
- Bioinformatics Scientists — Interpreting NGS data and variant catalogs for drug target discovery and validation
- Computational Biologists — Synthesizing multi-source genomic evidence to support target nomination and IND progression
- Clinical Development Scientists — Building regulatory-ready variant assessment packages for investigator meetings and submissions
- Genomics Project Managers — Coordinating variant interpretation deliverables across preclinical and clinical teams
- Research Scientists (Medicinal Chemistry) — Evaluating genetic targets and understanding molecular basis for compound screening
Best For
- GWAS data interpretation and rare variant prioritization for therapeutic target discovery
- WES/WGS variant calling output synthesis and cross-sample variant assessment
- Regulatory submission preparation requiring variant classification and disease association evidence
- Target tractability evaluation and druggability scoring for lead optimization decisions
- Cross-functional reporting on variant findings to non-bioinformatics stakeholders (medicinal chemistry, clinical operations)
You might also like
You can architect end-to-end bioinformatics analysis pipelines by translating your research question into algorithmic approaches, selecting and optimizing appropriate tools and parameters for your dataset, and validating results against biological expectations. This skill guides you through the complete decision tree from raw data to publication-ready interpretation, helping you avoid parameter overfitting, misinterpreted statistical thresholds, and algorithm selection errors that compromise research validity.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
You can upload or describe product designs and receive a comprehensive analysis of manufacturing feasibility, cost drivers, and prioritized optimization recommendations. The skill identifies design inefficiencies, material waste opportunities, assembly complexity challenges, and supply chain risks—giving you actionable steps to reduce costs and prevent production delays before they happen.
by kody-w
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
by kody-w
Upload production cycle time data and Claude will identify process bottlenecks, calculate efficiency metrics, and automatically generate detailed SOPs. You'll get a complete analysis of where time is wasted and structured work instructions that your team can immediately implement to reduce cycle time and improve consistency.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-w